|
1
|
Savona M and Talpaz M: Getting to the stem
of chronic myeloid leukaemia. Nat Rev Cancer. 8:341–350. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gesbert F, Sellers WR, Signoretti S, Loda
M and Griffin JD: BCR/ABL regulates expression of the
cyclin-dependent kinase inhibitor p27Kip1 through the
phosphatidylinositol 3-kinase/AKT pathway. J Biol Chem.
275:39223–39230. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lugo TG, Pendergast AM, Muller AJ and
Witte ON: Tyrosine kinase activity and transformation potency of
bcr-abl oncogene products. Science. 247:1079–1082. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Danial NN and Rothman P: JAK-STAT
signaling activated by Abl oncogenes. Oncogene. 19:2523–2531. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Airiau K, Mahon FX, Josselin M, Jeanneteau
M, Turcq B and Belloc F: ABT-737 increases tyrosine kinase
inhibitor-induced apoptosis in chronic myeloid leukemia cells
through XIAP downregulation and sensitizes CD34(+)CD38(−)population
to imatinib. Exp Hematol. 40:367–378. 2012. View Article : Google Scholar
|
|
6
|
Soliera AR, Mariani SA, Audia A, Lidonnici
MR, Addya S, Ferrari-Amorotti G, Cattelani S, Manzotti G,
Fragliasso V, Peterson L, et al: Gfi-1 inhibits proliferation and
colony formation of p210BCR/ABL- expressing cells via
transcriptional repression of STAT5 and Mcl-1. Leukemia.
26:1555–1563. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kantarjian HM, Talpaz M, Giles F, O’Brien
S and Cortes J: New insights into the pathophysiology of chronic
myeloid leukemia and imatinib resistance. Ann Intern Med.
145:913–923. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shah NP: Loss of response to imatinib:
mechanisms and management. Hematology Am Soc Hematol Educ Program.
183–187. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bradeen HA, Eide CA, O’Hare T, Johnson KJ,
Willis SG, Lee FY, Druker BJ and Deininger MW: Comparison of
imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107)
in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high
efficacy of drug combinations. Blood. 108:2332–2338. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Deguchi Y, Kimura S, Ashihara E, Niwa T,
Hodohara K, Fujiyama Y and Maekawa T: Comparison of imatinib,
dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.
Leuk Res. 32:980–983. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Meraldi P, Honda R and Nigg EA: Aurora
kinases link chromosome segregation and cell division to cancer
susceptibility. Curr Opin Genet Dev. 14:29–36. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Marumoto T, Zhang D and Saya H: Aurora-A -
a guardian of poles. Nat Rev Cancer. 5:42–50. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cammareri P, Scopelliti A, Todaro M,
Eterno V, Francescangeli F, Moyer MP, Agrusa A, Dieli F, Zeuner A
and Stassi G: Aurora-A is essential for the tumorigenic capacity
and chemoresistance of colorectal cancer stem cells. Cancer Res.
70:4655–4665. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shi Y, Reiman T, Li W, Maxwell CA, Sen S,
Pilarski L, Daniels TR, Penichet ML, Feldman R and Lichtenstein A:
Targeting aurora kinases as therapy in multiple myeloma. Blood.
109:3915–3921. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Giles FJ, Cortes J, Jones D, Bergstrom D,
Kantarjian H and Freedman SJ: MK-0457, a novel kinase inhibitor, is
active in patients with chronic myeloid leukemia or acute
lymphocytic leukemia with the T315I BCR-ABL mutation. Blood.
109:500–502. 2007. View Article : Google Scholar
|
|
16
|
Shah NP, Skaggs BJ, Branford S, Hughes TP,
Nicoll JM, Paquette RL and Sawyers CL: Sequential ABL kinase
inhibitor therapy selects for compound drug-resistant BCR-ABL
mutations with altered oncogenic potency. J Clin Invest.
117:2562–2569. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zheng FM, Long ZJ, Hou ZJ, Luo Y, Xu LZ,
Xia JL, Lai XJ, Liu JW, Wang X, Kamran M, et al: A novel small
molecule aurora kinase inhibitor attenuates breast tumor-initiating
cells and overcomes drug resistance. Mol Cancer Ther. 13:1991–2003.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Luo Y, Deng YQ, Wang J, Long ZJ, Tu ZC,
Peng W, Zhang JQ, Liu Q and Lu G: Design, synthesis and
bioevaluation of N-trisubstituted pyrimidine derivatives as potent
aurora A kinase inhibitors. Eur J Med Chem. 78:65–71. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Melo JV and Chuah C: Resistance to
imatinib mesylate in chronic myeloid leukaemia. Cancer Lett.
249:121–132. 2007. View Article : Google Scholar
|
|
20
|
Branford S: Chronic myeloid leukemia:
molecular monitoring in clinical practice. Hematology Am Soc
Hematol Educ Program. 376–383. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nicolini FE, Hayette S, Corm S, Bachy E,
Bories D, Tulliez M, Guilhot F, Legros L, Maloisel F, Kiladjian JJ,
et al: Clinical outcome of 27 imatinib mesylate-resistant chronic
myelogenous leukemia patients harboring a T315I BCR-ABL mutation.
Haematologica. 92:1238–1241. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Soverini S, Colarossi S, Gnani A, Rosti G,
Castagnetti F, Poerio A, Iacobucci I, Amabile M, Abruzzese E,
Orlandi E, et al: Contribution of ABL kinase domain mutations to
imatinib resistance in different subsets of Philadelphia-positive
patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Clin Cancer Res. 12:7374–7379. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Carmena M and Earnshaw WC: The cellular
geography of aurora kinases. Nat Rev Mol Cell Biol. 4:842–854.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu LL, Long ZJ, Wang LX, Zheng FM, Fang
ZG, Yan M, Xu DF, Chen JJ, Wang SW, Lin DJ, et al: Inhibition of
mTOR pathway sensitizes acute myeloid leukemia cells to aurora
inhibitors by suppression of glycolytic metabolism. Mol Cancer Res.
11:1326–1336. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Long ZJ, Xu J, Yan M, Zhang JG, Guan Z, Xu
DZ, Wang XR, Yao J, Zheng FM, Chu GL, et al: ZM 447439 inhibition
of aurora kinase induces Hep2 cancer cell apoptosis in
three-dimensional culture. Cell Cycle. 7:1473–1479. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu DR, Huang S, Long ZJ, Chen JJ, Zou ZZ,
Li J, Lin DJ and Liu Q: Inhibition of mitotic kinase Aurora
suppresses Akt-1 activation and induces apoptotic cell death in
all-trans retinoid acid-resistant acute promyelocytic leukemia
cells. J Transl Med. 9:742011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Costello RT, Mallet F, Gaugler B, Sainty
D, Arnoulet C, Gastaut JA and Olive D: Human acute myeloid leukemia
CD34+/CD38− progenitor cells have decreased
sensitivity to chemotherapy and Fas-induced apoptosis, reduced
immunogenicity, and impaired dendritic cell transformation
capacities. Cancer Res. 60:4403–4411. 2000.PubMed/NCBI
|
|
28
|
Rao J, Xu DR, Zheng FM, Long ZJ, Huang SS,
Wu X, Zhou WH, Huang RW and Liu Q: Curcumin reduces expression of
Bcl-2, leading to apoptosis in daunorubicin-insensitive
CD34+ acute myeloid leukemia cell lines and primary
sorted CD34+ acute myeloid leukemia cells. J Transl Med.
9:712011. View Article : Google Scholar
|
|
29
|
Yang J, Ikezoe T, Nishioka C, Nobumoto A,
Udaka K and Yokoyama A: CD34+/CD38− acute
myelogenous leukemia cells aberrantly express Aurora kinase A. Int
J Cancer. 133:2706–2719. 2013.PubMed/NCBI
|
|
30
|
Kim SJ, Jang JE, Cheong JW, Eom JI, Jeung
HK, Kim Y, Hwang DY and Min YH: Aurora A kinase expression is
increased in leukemia stem cells, and a selective Aurora A kinase
inhibitor enhances Ara-C-induced apoptosis in acute myeloid
leukemia stem cells. Korean J Hematol. 47:178–185. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ye D, Garcia-Manero G, Kantarjian HM, Xiao
L, Vadhan-Raj S, Fernandez MH, Nguyen MH, Medeiros LJ and
Bueso-Ramos CE: Analysis of Aurora kinase A expression in CD34(+)
blast cells isolated from patients with myelodysplastic syndromes
and acute myeloid leukemia. J Hematop. 2:2–8. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ouchi M, Fujiuchi N, Sasai K, Katayama H,
Minamishima YA, Ongusaha PP, Deng C, Sen S, Lee SW and Ouchi T:
BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M
transition. J Biol Chem. 279:19643–19648. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Katayama H, Wang J, Treekitkarnmongkol W,
Kawai H, Sasai K, Zhang H, Wang H, Adams HP, Jiang S, Chakraborty
SN, et al: Aurora kinase-A inactivates DNA damage-induced apoptosis
and spindle assembly checkpoint response functions of p73. Cancer
Cell. 21:196–211. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cheng C, Liu ZG, Zhang H, Xie JD, Chen XG,
Zhao XQ, Wang F, Liang YJ, Chen LK, Singh S, et al: Enhancing
chemosensitivity in ABCB1- and ABCG2-overexpressing cells and
cancer stem-like cells by an Aurora kinase inhibitor CCT129202. Mol
Pharm. 9:1971–1982. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kelly KR, Ecsedy J, Medina E, et al: The
novel Aurora A kinase inhibitor MLN8237 is active in resistant
chronic myeloid leukaemia and significantly increases the efficacy
of nilotinib. J Cell Mol Med. 15:2057–2070. 2011. View Article : Google Scholar
|
|
36
|
Mohan P, Castellsague J, Jiang J, Allen K,
Chen H, Nemirovsky O, Spyra M, Hu K, Kluwe L, Pujana MA, et al:
Genomic imbalance of HMMR/RHAMM regulates the sensitivity and
response of malignant peripheral nerve sheath tumour cells to
aurora kinase inhibition. Oncotarget. 4:80–93. 2013.PubMed/NCBI
|
|
37
|
Dai Y, Chen S, Venditti CA, Pei XY, Nguyen
TK, Dent P and Grant S: Vorinostat synergistically potentiates
MK-0457 lethality in chronic myelogenous leukemia cells sensitive
and resistant to imatinib mesylate. Blood. 112:793–804. 2008.
View Article : Google Scholar : PubMed/NCBI
|
